Delving into the Latest Updates on TR128 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Mechanism

RAS inhibitors(RAS type GTPase family inhibitors), Raf kinase inhibitors(RAF serine/threonine protein kinase inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Tarapeutics Science Inc

Active Organization

Tarapeutics Science Inc

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This is a open-label, 3+3 design, dose escalation and expansion, phase I study, to evaluate the safety and tolerability, and to determine the Recommended Phase II Dose (RP2D) of TR128 when administered qd in patients with advanced solid tumors. Up to 5 cohorts of 3-6 patients each will be treated in dose escalation phase of the study. One cycle is 28 days. Dose expansion phase to further evaluate the safety, tolerability and preliminary anti-tumor activity of TR128 at the RP2D.

Start Date23 Feb 2024

Sponsor / Collaborator

Tarapeutics Science Inc

CTR20230464 / RecruitingPhase 1

TR128 治疗晚期实体瘤患者中的安全性、耐受性和药代动力学的Ⅰ期临床试验

[Translation] A Phase I clinical trial to investigate the safety, tolerability and pharmacokinetics of TR128 in patients with advanced solid tumors

评估TR128胶囊单药口服给药在晚期实体瘤患者中的安全性和耐受性，确定剂量限制性毒性（DLT）、最大耐受剂量（MTD）和II期临床试验推荐剂量（RP2D）

[Translation]

To evaluate the safety and tolerability of TR128 capsules as a single oral agent in patients with advanced solid tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended dose for Phase II clinical trials (RP2D)

Start Date05 Feb 2024

Sponsor / Collaborator

Tarapeutics Science Inc

100 Clinical Results associated with TR128

Login to view more data

100 Translational Medicine associated with TR128

Login to view more data

100 Patents (Medical) associated with TR128

Login to view more data

100 Deals associated with TR128

Login to view more data